MinorOral hypoglycemic agents. Sulfonylureas×Imidazole derivatives (antiprotozoal / antibacterial)
Updated · Methodology
Mechanism
In the liver, enzymes metabolise almost all of the glibenclamide, and CYP2C9 contributes most (glibenclamide SmPC, European Medicines Agency, EMA). The metronidazole documents describe no effect on CYP2C9 and do not name glibenclamide or other sulfonylureas (metronidazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and Flagyl label, US Food and Drug Administration, FDA). According to the glibenclamide documents, highly protein-bound drugs can potentiate its effect, while metronidazole is less than 20% bound to plasma proteins (glibenclamide SmPC, EMA, and glyburide label, FDA; metronidazole SmPC, AEMPS). Metronidazole is not on the lists of drugs that change the glucose-lowering effect of glibenclamide (glibenclamide SmPC, EMA, and glyburide label, FDA).
Symptoms
The documents describe no symptoms of this combination. Glibenclamide itself can cause hypoglycaemia. It is more likely with too little food, after severe or prolonged exercise, after alcohol and when more than one glucose-lowering drug is used (glyburide label, US Food and Drug Administration, FDA). Severe hypoglycaemia shows as seizures, coma and other neurological disturbances (glibenclamide SmPC, European Medicines Agency, EMA).
Management
According to the documents, the combination is acceptable, and the doses of metronidazole and glibenclamide need no change. No document names the pair (metronidazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and Flagyl label, US Food and Drug Administration, FDA; glibenclamide SmPC, European Medicines Agency, EMA, and glyburide label, FDA). Check blood glucose regularly during glibenclamide treatment, as without metronidazole (glibenclamide SmPC, EMA). When glucose is measured in a laboratory, keep in mind that metronidazole can give falsely low or even zero results. This applies to assays based on the oxidation and reduction of nicotinamide adenine dinucleotide (NAD+ and NADH), including the hexokinase glucose method (metronidazole SmPC, AEMPS, and Flagyl label, FDA). Explain to the patient the risk of hypoglycaemia, its symptoms and what can trigger it (glyburide label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Flagyl (metronidazole) capsules – Prescribing Information (2026)– FDA, DailyMed SPL, Pfizer, Precautions (Drug Interactions)
- AEMPS: Ficha técnica: Metronidazol, Flagyl 250 mg comprimidos (nº registro 35034), sección 4.5 (2025)– AEMPS, CIMA, nº registro 35034, revisión 08/2025, secciones 4.3, 4.4, 4.5 y 4.8
- FDA: Glyburide tablets, Teva (glyburide) prescribing information (2015)– FDA, DailyMed setid a56f100f-0f42-4188-81ab-04644b824040, revisión 05/2015 (versión 19), PRECAUTIONS (Hypoglycemia, Geriatric Use)
- EMA: Ficha técnica: Glibenclamida (EU/1/18/1279), sección 4.5 (2026)– EMA, Amglidia 0,6 mg/ml suspensión oral (AMMTek, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1181279001, consultada 29.10.2026, sin fecha de revisión en CIMA, secciones 4.4, 4.5, 4.9 y 5.2